| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| FIDO | 109 | Supported by Genentech as an Investigator-Initiated Study | 2014 |
Peden MC, Suer IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122:803-808. https://www.aaojournal.org/article/S0161-6420(14)01091-4/fulltext |